Literature DB >> 8592044

Use of pentoxifylline in assisted reproductive technology.

H Tournaye1, P Devroey, M Camus, M Van der Linden, R Janssens, A Van Steirteghem.   

Abstract

Methods for improving the fertilizing potential of the spermatozoa in human in-vitro fertilization (IVF) include the stimulation of sperm function in vitro. Metabolic stimulation in vitro has become a major issue in assisted reproductive technology (ART). Here, we review our research on the unselective use of pentoxifylline in IVF for male-factor infertility. Data from our controlled studies indicate that an indiscriminate use of 3.6 mM pentoxifylline, alone or in combination with 3.0 mM 2-deoxyadenosine, is not beneficial in enhancing fertilization rates in zero and poor in-vitro fertilizers or in the presence of antisperm antibodies. An assessment of the effects of pentoxifylline on sperm function prior to IVF may ensure a more rational use of these compounds in selected cases undergoing ART. At present, however, controlled studies in subgroups of patients selected by functional testing are still lacking.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592044     DOI: 10.1093/humrep/10.suppl_1.72

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  3 in total

Review 1.  [Drug therapy options for oligoasthenoteratozoospermia syndrome].

Authors:  M Trottmann; F M Köhn; M Dickmann; C G Stief; A J Becker
Journal:  Urologe A       Date:  2011-01       Impact factor: 0.639

2.  Pentoxifylline initiates motility in spontaneously immotile epididymal and testicular spermatozoa and allows normal fertilization, pregnancy, and birth after intracytoplasmic sperm injection.

Authors:  P Terriou; E Hans; C Giorgetti; J L Spach; J Salzmann; V Urrutia; R Roulier
Journal:  J Assist Reprod Genet       Date:  2000-04       Impact factor: 3.412

Review 3.  Sperm preparation for ART.

Authors:  Ralf R Henkel; Wolf-Bernhard Schill
Journal:  Reprod Biol Endocrinol       Date:  2003-11-14       Impact factor: 5.211

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.